157837-63-3

Upstream product

• 4098-66-2 2,4-dimethyl-pentanedioic acid dimethyl ester 
• 82917-26-8 [2R,4S]-5-hydroxy-2,4-dimethyl-pentanoic acid methyl ester 
• 58479-61-1 tert-butylchlorodiphenylsilane 

Downstream Products

• 157837-64-4 (2R,4S)-5-{[tert-butyl(diphenyl)silyl]oxy}-2,4-dimethylpentan-1-ol 
• 157837-65-5 (2R,4S)-5-{[tert-butyl(diphenyl)silyl]oxy}-2,4-dimethylpentanal 
• 157837-58-6 tert-Butyl-((2S,4R)-4-[1,3]dithian-2-yl-2-methyl-pentyloxy)-diphenyl-silane 
• 164592-86-3 (E)-(2R,3S,6R,9S,12R,14S)-9-(tert-Butyl-dimethyl-silanyloxy)-3-hydroxy-1-((1S,3R,4R)-3-methoxy-4-triisopropylsilanyloxy-cyclohexyl)-2,6,8,12,14-pentamethyl-hexadec-7-en-15-yne-5,11-dione 
• 164592-84-1 (2S,3R)-1-(2-{(E)-(1R,4S)-4-(tert-Butyl-dimethyl-silanyloxy)-5-[2-((1R,3S)-1,3-dimethyl-pent-4-ynyl)-[1,3]dithian-2-yl]-1,3-dimethyl-pent-2-enyl}-[1,3]dithian-2-yl)-4-((1S,3R,4R)-3-methoxy-4-triisopropylsilanyloxy-cyclohexyl)-3-methyl-butan-2-ol 
• 164592-59-0 (E)-(2S,5R)-1-[2-((1R,3S)-4,4-Dimethoxy-1,3-dimethyl-butyl)-[1,3]dithian-2-yl]-5-{2-[(2S,3R)-2-(4-methoxy-benzyloxy)-4-((1S,3R,4R)-3-methoxy-4-triisopropylsilanyloxy-cyclohexyl)-3-methyl-butyl]-[1,3]dithian-2-yl}-3-methyl-hex-3-en-2-ol 
• 164592-82-9 C₅₇H₁₀₀O₅S₄Si₂ 
• 164592-80-7 C₅₆H₁₀₀O₆S₄Si₂ 
• 164592-60-3 C₅₈H₁₀₆O₇S₄Si₂ 
• 164592-79-4 C₅₇H₁₀₂O₇S₄Si₂ 
• 186449-08-1 C₅₉H₁₀₈O₈S₄Si₂ 
• 186449-04-7 2-[(E)-(1S,2R,5R)-2-(tert-Butyl-dimethyl-silanyloxy)-5-[1,3]dithian-2-yl-1-methoxy-3-methyl-hex-3-enyl]-2-[(1R,3S)-4-(tert-butyl-diphenyl-silanyloxy)-1,3-dimethyl-butyl]-[1,3]dithiane 
• 186449-00-3 (E)-(1S,2R,5R)-2-(tert-Butyl-diphenyl-silanyloxy)-1-{2-[(1R,3S)-4-(tert-butyl-diphenyl-silanyloxy)-1,3-dimethyl-butyl]-[1,3]dithian-2-yl}-5-[1,3]dithian-2-yl-3-methyl-hex-3-en-1-ol 
• 186449-18-3 C₅₇H₁₀₀Br₂O₅S₄Si₂ 

Relevant academic research and scientific papers

A unified total synthesis of the immunomodulators (-)-rapamycin and (-)-27-demethoxyrapamycin: Construction of the C(21-42) perimeters

A total synthesis of the potent, naturally occurring immunomodulators (-)-rapamycin (1) and (-)-27-demethoxyrapamycin (2) has been achieved via a unified, highly convergent synthetic strategy. Both targets were elaborated from common building blocks A-E,

Rapamycin synthetic studies. 2. Elaboration of the C(10)-C(26) perimeter

The C(10)-C(26) subunit of the potent immunomodulator rapamycin has been constructed via a highly convergent approach, exploiting palladium-mediated σ-bond formation to generate the sensitive triene moiety.